TREA

Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives

Follow

Information

  • Patent Application
  • 20070197621
  • Publication Number
    20070197621
  • Date Filed
    January 19, 2007
    18 years ago
  • Date Published
    August 23, 2007
    17 years ago
Information
Abstract
The present invention relates a method for treating depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders which comprises administering to an individual a therapeutically effective amount of a compound of formula I
Description
Claims
  • 1. A method for treating a disorder selected from the group consisting of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders comprising administering to an individual a therapeutically effective amount of a compound of formula I
  • 2. The method of claim 1, wherein A is phenyl and R is other than hydrogen.
  • 3. The method of claim 2, wherein the compound is selected from the group consisting of
  • 4. The method of claim 2, wherein the compound is selected from the group consisting of
  • 5. The method of claim 2, wherein the compound is selected from the group consisting of
  • 6. The method of claim 2, wherein the compound is selected from the group consisting of
  • 7. The method of claim 2, wherein the compound is selected from the group consisting of
  • 8. The method of claim 1, wherein A is naphthyl.
  • 9. The method of claim 8, wherein the compound is selected from the group consisting of
  • 10. The method of claim 1, wherein A is benzofuranyl.
  • 11. The method of claim 10, wherein the compound is selected from the group consisting of
  • 12. The method of claim 1, wherein A is thiophenyl.
  • 13. The method of claim 12, wherein the compound is selected from the group consisting of
  • 14. The method of claim 1, wherein A is benzo[b]thiophenyl.
  • 15. The method of claim 14, wherein the compound is
  • 16. The method of claim 1, wherein A is indolyl-3-yl.
  • 17. The method of claim 16, wherein the compound is
  • 18. A compound of formula I
  • 19. The compound of claim 18, wherein A is phenyl and R is other than hydrogen.
  • 20. The compound of claim 19, selected from the group consisting of
  • 21. The compound of claim 19, selected from the group consisting of
  • 22. The compound of claim 19, selected from the group consisting of
  • 23. The compound of claim 18, wherein A is naphthyl.
  • 24. The compound of claim 23, selected from the group consisting of
  • 25. The compound of claim 18, wherein A is benzofuranyl.
  • 26. The compound of claim 25, selected from the group consisting of
  • 27. The compound of claim 18, wherein A is thiophenyl.
  • 28. The compound of claim 27, selected from the group consisting of
  • 29. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I
Priority Claims (1)
Number Date Country Kind
06100955.1 Jan 2006 EP regional